Juno Therapeutics

Hired a Bio-Link StudentDescription: 

The company leverages two technologies—CARs and TCRs—to activate a patient’s own T cells so that they attack cancer cells. Through genetic engineering, we insert a gene for a particular CAR or TCR construct into the T cell that enables it to recognize cancer cells. Our CAR technology directs T cells to recognize cancer cells based on the expression of specific proteins located on the cell surface, whereas our TCR technology provides the T cells with a specific T cell receptor to recognize protein fragments derived from either the surface or inside the cell.

Location(s): 
Juno Therapeutics, Inc.
Bothell WA
United States
Waltham MA
United States